RESUMO
Objective: To determine the efficacy and safety of Q-switched Nd:YAG 1064nm laser for melasma treatment
Methods: Thirty patients with melasma were treated with Qs-Nd:YAG laser 1064nm, 6mm spot size with 2.5-3.2J/cm[2] for four sessions 2 weeks apart. Pigmentation was assessed objectively with photographic evaluation and by decrease in the MASI score and subjectively by decrease in pigmentation assessed by grades of improvement. Patients were assessed 8 weeks after the last session. Adverse effects were recorded at each visit
Results: After four sessions, 20 [65%] of patients showed marked improvement, 6 [20%] showed moderate improvement and 4 [13%] showed poor response after 14 weeks of treatment. No significant side effects were noted. A decreased MASI score was significant at the end of 14 week's evaluation [p<0.05]. Recurrence occurred in only 10% of patients who were advised to wear sunblock afterwards
Conclusion: Q-switched Nd:YAG 1064nm laser is an effective and safe treatment of melasma in our local population
RESUMO
Pyoderma gangrenosum [PG] is an uncommon ulcerative cutaneous condition of heterogeneous etiology. It is characterized by rapid progression of painful necrolytic ulcer
It is associated with systemic diseases in at least 50% of patients. Diagnosis is made by exclusion of other causes of similar appearing cutaneous ulcerations including infections, malignancy, etc. In our case pyoderma gangrenosum was associated with ulcerative colitis
RESUMO
Objective: To evaluate the efficacy and safety of autologous platelet rich plasma [PRP] in treatment of limited alopecia areata in local population
Methods: We performed a prospective study of 20 patients with Alopecia Areata. Both females and males with one or multiple patches of alopecia were included. Autologous PRP was injected once a month for three months. Primary endpoint was regrowth of hair. Digital phtographs were taken before treatment and after each visit. Patients were further followed up for 6 months after treatment for any relapse or side effect. Results were assessed clinically and using digital photographs
Results: Out of 20 patients, 6 [30%] had excellent response, 5 [25%] with good response, 4 [20%] with fair and 5 [25%] poor response. Mild pain at the site of injection was noted for 5 to 30 min at injection site. No other side effect was noted nor reported by any of the patients. Patient compliance and satisfaction was good and all patients completed the treatment
Conclusion: PRP is safe, low-cost and effective treatment of alopecia areata
RESUMO
Disseminated superficial actinic porokeratosis [DSAP] is characterized by small, atrophic patches with distinctive keratin rims that occur on sun-exposed areas of the extremities, shoulders, and back. The diagnosis is based on the histopathologic finding of a cornoid lamella, absence of a granular layer, and often a thin epidermis. It is associated with exposure to ultraviolet radiation. We report a case of DSAP in our setting
Assuntos
Adulto , Feminino , Humanos , Poroceratose/patologia , Poroceratose/genética , Poroceratose/terapia , QueratinócitosRESUMO
Buerger's disease is an occlusive vasculopathy affecting small- to medium-sized blood vessels. The disease usually affects smokers. Clinically, it is characterized by features related to ischemia. If untreated gangrene and amputation may supervene. A wide variety of therapeutic options ranging from vasodilators to sympathectomy are useful We, herein, report an adult female with this disease, who underwent sympathectomy for relief of her symptoms
RESUMO
Background: Topical steroids are an established therapy for localized psoriasis. Calcipotriol [vitamin D[3] analogue] is a relatively newer addition to the therapeutic armamentarium of psoriasis. We compared the efficacy and safety of calcipotriol 0.005% ointment and betamethasone valerate 0.1% ointment in the treatment of chronic plaque psoriasis
Patients and methods: One hundred diagnosed cases of chronic plaque psoriasis, 50 patients in each group, were enrolled in the study. Age range was 20-55 years for calcipotriol group with a mean of 33.6 years and 15-52 years for betamethasone valerate group with a mean age of 32.6 years. Male to female ratio was 1.17:1 in calcipotriol and 2.13:1 in betamethasone group. Patients in both groups were advised to apply the topical agents twice daily for 6 weeks. They were followed up at 2, 4 and 6 weeks. The assessment was made on the basis of PASI. Overall response was graded as clearance [>70% reduction in PASI], marked improvement [60-70% reduction in PASI], mild improvement [50-60% reduction in PASI], no change and worsening
Results: The mean PASI reduction in calcipotriol group was from 6.33 at week 0 to 1.90 at week 6, whereas betamethasone valerate ointment group showed a decrease in mean PASI from 6.22 at week 0 to 2.26 at the end of treatment. The scores for erythema, infiltration and desquamation at each follow-up i.e. 2, 4 and 6 weeks were comparable in both groups. All the three parameters were effectively reduced by both the topical modalities during six weeks treatment period, but the difference was not significant statistically when compared with each other [p>0.05]. Side effects were observed with both topical agents during 6 weeks of application. Most commonly observed side effects with calcipotriol were persistent lesional erythema in 10 [20%], lesional/perilesional irritation in 7 [14%], pruritus in 4 [8%] and folliculitis in 2 [4%] of the patients. Adverse events noted with betamethasone valerate ointment were atrophy in 6 [12%], folliculitis in 5 [10%], persistent erythema in 4 [8%], pruritus in 2 [4%] and lesional irritation in 1 [2%] of the patients
Conclusion: Topical calcipotriol is as efficacious and safe as betamethasone valerate in the treatment of chronic plaque psoriasis